Neuphoria Therapeutics Inc. (NEUP)
Nasdaq: NEUP · Pharmaceutical Preparations · Burlington, MA · filing with the SEC since 2002
Who runs Neuphoria Therapeutics Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Papapetropoulos Spyros
President and CEO. First filing Jul 2024, latest Sep 2, 2025, 0 filings in all.
Officers reporting now
1
of 5 people with a filing in the last fifteen months
Directors reporting now
4
7 people on the record since 2024
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Papapetropoulos Spyros | President and CEO | Jul 2024 | Sep 2, 2025 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Davies Peter Miles Winston | director | Jul 2024 | Jan 21, 2026 | none |
| Fisher Alan | director | Jul 2024 | Jan 21, 2026 | none |
| Ryan Jane | director | Jul 2024 | Jan 21, 2026 | none |
| Wilson David Ian | director | Jul 2024 | Jan 21, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% owner | Oct 2025 | Oct 23, 2025 | none |
| Nichols Weston | 10% owner | Oct 2025 | Oct 23, 2025 | none |
Earlier names on the record2, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.